J
John Hansen
Researcher at Kaiser Permanente
Publications - 57
Citations - 5910
John Hansen is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Vaccination & Internal medicine. The author has an hindex of 24, co-authored 48 publications receiving 5639 citations.
Papers
More filters
Journal ArticleDOI
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
Steven Black,Henry R. Shinefield,Bruce Fireman,Edwin Lewis,Paula Ray,John Hansen,Laura Elvin,Kathy M. Ensor,Jill G. Hackell,George R. Siber,Frank J. Malinoski,Dace V. Madore,Ih Chang,Robert Kohberger,Wendy J. Watson,Robert Austrian,Kathy Edwards +16 more
TL;DR: The Wyeth Lederle as discussed by the authors determined the efficacy, safety and immunogenicity of the CRM197 pneumococcal conjugate vaccine against invasive disease caused by vaccine serotypes and to determine the effectiveness of this vaccine against clinical episodes of otitis media.
Journal ArticleDOI
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.
Steven Black,Henry R. Shinefield,Stella Ling,John Hansen,Bruce Fireman,David Spring,Jack Noyes,Edwin Lewis,Paula Ray,Janelle Lee,Jill G. Hackell +10 more
TL;DR: The heptavalent CRM197 pneumococcal conjugate vaccine was given to infants at 2, 4, 6 and 12 to 15 months of age in a randomized, double blind trial and was effective in reducing the risk of pneumonia in young children.
Journal ArticleDOI
Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.
Steven Black,Henry R. Shinefield,Roger Baxter,Robert Austrian,Laura Bracken,John Hansen,Edwin Lewis,Bruce Fireman +7 more
TL;DR: The PNCV7 vaccine is highly effective in reducing the burden of pneumococcal disease in children <5 years of age, and there is evidence of a herd effect as well as a decrease in the antibiotic resistant in strains causing disease.
Journal ArticleDOI
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
Henry R. Shinefield,Steven Black,Paula Ray,Ih Chang,Ned Lewis,Bruce Fireman,Jill G. Hackell,Peter R. Paradiso,George R. Siber,Robert Kohberger,Dace V. Madore,Frank J. Malinowski,Alan Kimura,Chinh Le,Irene Landaw,Janet Aguilar,John Hansen +16 more
TL;DR: It is concluded that PNCRM7 vaccine was safe and immunogenic and when this vaccine was administered concurrently at the booster dose with DTaP and HbOC vaccines, lower antibody titers were noted for some of the antigens when compared with the antibody response when PNC RM7 was given separately.
Journal ArticleDOI
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs.
John Hansen,Steven Black,Henry R. Shinefield,Thomas Cherian,Jane Benson,Bruce Fireman,Edwin Lewis,Paula Ray,Janelle Lee +8 more
TL;DR: Using WHO criteria for reading of radiographs increased point estimates of vaccine efficacy presumably as a result of improved specificity.